Study identifier:RDEA3170-112
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1, Randomized, Open-Label Study in Healthy Adult Male Subjects to Assess the Pharmacokinetics and Pharmacodynamics of RDEA3170
Gout
Phase 1
Yes
RDEA3170 4.5 mg, RDEA3170 6 mg, RDEA3170 12 mg
Male
40
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Nov 2015 by Ardea Biosciences, Inc.
Ardea Biosciences, Inc.
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Single Dose Single dose of RDEA3170 4.5 mg, RDEA3170 6 mg or RDEA3170 12 mg on Days 1, 5 and 9. | - |
Experimental: Multiple Dose RDEA3170 12 mg once daily (qd) | - |
Experimental: Single Dose Food Effect Since dose of RDEA3170 6 mg administered in fed or fasted state on Day 1 and Day 8. | - |